JP7796718B2 - 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法 - Google Patents

閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法

Info

Publication number
JP7796718B2
JP7796718B2 JP2023501090A JP2023501090A JP7796718B2 JP 7796718 B2 JP7796718 B2 JP 7796718B2 JP 2023501090 A JP2023501090 A JP 2023501090A JP 2023501090 A JP2023501090 A JP 2023501090A JP 7796718 B2 JP7796718 B2 JP 7796718B2
Authority
JP
Japan
Prior art keywords
minutes
pharmaceutically acceptable
acceptable salt
thc
osa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533289A (ja
JP2023533289A5 (https=
Inventor
ブリークレイ，マーク・ロバート
アガーワル，スダンシュ
レイサム，ジョエル・ブラッドリー
Original Assignee
インカネックス・ヘルスケア・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by インカネックス・ヘルスケア・リミテッド filed Critical インカネックス・ヘルスケア・リミテッド
Publication of JP2023533289A publication Critical patent/JP2023533289A/ja
Publication of JP2023533289A5 publication Critical patent/JP2023533289A5/ja
Application granted granted Critical
Publication of JP7796718B2 publication Critical patent/JP7796718B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023501090A 2020-07-09 2021-07-09 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法 Active JP7796718B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902368 2020-07-09
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (3)

Publication Number Publication Date
JP2023533289A JP2023533289A (ja) 2023-08-02
JP2023533289A5 JP2023533289A5 (https=) 2024-07-09
JP7796718B2 true JP7796718B2 (ja) 2026-01-09

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501090A Active JP7796718B2 (ja) 2020-07-09 2021-07-09 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法

Country Status (8)

Country Link
US (1) US20230310364A1 (https=)
EP (1) EP4178568A4 (https=)
JP (1) JP7796718B2 (https=)
AU (1) AU2021306424A1 (https=)
CA (1) CA3182528A1 (https=)
CO (1) CO2023000118A2 (https=)
IL (1) IL299212A (https=)
WO (1) WO2022006636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520386A (ja) * 2022-06-21 2025-07-03 アプニメッド，インコーポレイテッド（デラウェア） カンナビノイドおよびカルボニックアンヒドラーゼ阻害剤の組合せを用いた睡眠時無呼吸を治療する方法
EP4626410A1 (en) * 2022-11-29 2025-10-08 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
CA3126772A1 (en) * 2018-01-29 2019-08-01 Evero Compositions and methods for treating obstructive sleep apnea
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
US20240189328A1 (en) * 2021-04-16 2024-06-13 Apnimed, Inc. (Delaware) Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bradley A. Edwards et al.，Sleep，2013年，Vol.36, No.2，DOI:10.5665/sleep.2390
David W. Carley et al.，Sleep，2018年，Vol.41, No.1，DOI:10.1093/sleep/zsx184

Also Published As

Publication number Publication date
IL299212A (en) 2023-02-01
CA3182528A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17
JP2023533289A (ja) 2023-08-02
WO2022006636A1 (en) 2022-01-13
CO2023000118A2 (es) 2023-04-17
AU2021306424A1 (en) 2023-01-19
EP4178568A4 (en) 2024-10-16
US20230310364A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP7796718B2 (ja) 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法
US6207190B1 (en) Dosage forms for the treatment of the chronic glaucomas
York Design of dosage forms
JPH09503778A (ja) 鎮痛剤およびその使用
JP3977724B2 (ja) 医薬組成物
MX2011007759A (es) Analogos de bumetanida, furosemida, piretanida, azosemida y torsemida, composiciones y metodos de uso.
WO2012166909A1 (en) Compositions and methods for treating breathing control disorders or diseases
CN109069495A (zh) 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
TW524690B (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
US6005009A (en) Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
CN120549929A (zh) 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
AU2024205127B2 (en) Compositions and methods for treating epilepsy
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP5680412B2 (ja) レオヌリンの使用およびその組成物
AU2006305309A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
JP2025530256A (ja) ストレス関連障害の治療のためのｍｄｍａの使用
CN110974828A (zh) 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物
EP1944030B1 (en) Agent for treatment of schizophrenia
CN1625402A (zh) 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途
JP4355967B2 (ja) 医薬組成物
KR20250145687A (ko) 류마티스 관절염의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
KR20250141841A (ko) 다발성 경화증의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
DE69919191T2 (de) Heilmittel für die stenose des rückenmarkkanals
KR20250149771A (ko) 위장관 장애의 치료 및 면역조절제로서의 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
JP7823051B2 (ja) 高血圧を処置する為の医薬組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796718

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150